1. Home
  2. KRMD vs ADAG Comparison

KRMD vs ADAG Comparison

Compare KRMD & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KORU Medical Systems Inc. (DE)

KRMD

KORU Medical Systems Inc. (DE)

HOLD

Current Price

$4.23

Market Cap

189.3M

Sector

Health Care

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$3.74

Market Cap

254.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRMD
ADAG
Founded
1980
2011
Country
United States
China
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
189.3M
254.4M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
KRMD
ADAG
Price
$4.23
$3.74
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$6.50
$8.25
AVG Volume (30 Days)
117.5K
105.7K
Earning Date
05-06-2026
04-01-2026
Dividend Yield
N/A
N/A
EPS Growth
53.85
N/A
EPS
N/A
N/A
Revenue
$41,127,366.00
N/A
Revenue This Year
$20.32
N/A
Revenue Next Year
$17.37
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.23
N/A
52 Week Low
$2.68
$1.44
52 Week High
$6.61
$4.75

Technical Indicators

Market Signals
Indicator
KRMD
ADAG
Relative Strength Index (RSI) 53.95 53.40
Support Level $3.87 $3.31
Resistance Level $4.34 $3.99
Average True Range (ATR) 0.17 0.30
MACD 0.04 0.02
Stochastic Oscillator 45.45 75.61

Price Performance

Historical Comparison
KRMD
ADAG

About KRMD KORU Medical Systems Inc. (DE)

KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: